Graf Akcie CLVS (Clovis Oncology Inc). Diskuze k akciím CLVS. Aktuální informace CLVS.

Základní informace o společnosti Clovis Oncology Inc (Akcie CLVS)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 465.31M
Hodnota podniku (EV) 943.01M
Tržby 156.944M
EBITDA -245.55
Zisk -310.36
Růst v tržbách Q/Q -7.69 %
Růst v tržbách Y/Y -1.52 %
P/E (Cena vůči ziskům) N/A
Forward P/E -0.02
EV/Sales 6.01
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 3.25
P/FCF N/A
Price/Book -3.21
Účetní hodnota na akcii -1.38
Hotovost na akcii 2.09
FCF vůči ceně -43.00 %
Počet zaměstnanců 429
Tržba na zaměstnance 365.837k
Profit margin -224.41 %
Operating margin -161.28 %
Gross margin 74.89 %
EBIT margin -178.36 %
EBITDA margin -156.45 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -46.96 %
EPS - Očekávaný růst příští rok -44.94 %
Return on assets -53.52 %
Return on equity 165.49 %
ROIC -53.21 %
ROCE -70.27 %
Dluhy/Equity -4.81
Čistý dluh/EBITDA -7.06
Current ratio 1.70
Quick Ratio 0.96
Volatilita 4.08
Beta 1.16
RSI 48.36
Cílová cena analytiků 7
Známka akcie (dle analytiků) 3.43
Insider ownership 1.84 %
Institutional ownership 50.42 %
Počet akcií 118.41M
Procento shortovaných akcií 30.23 %
Short ratio 7.42 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2011
Země United States

Finanční výsledky akcie CLVS

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$143.006$95.388$55.511$0.078-$13.625
Cost Of Goods Sold$34.686$22.074$11.737$0.07--
Gross Profit$108.32$73.314$43.774$0.008-$13.625
Research And Development Expenses$283.146$231.347$142.498$251.129$269.251$137.705
SG&A Expenses$182.769$175.781$138.907$40.731$30.524$21.457
Other Operating Income Or Expenses$-9.711-----
Operating Expenses$519.752$429.202$293.142$372.811$376.721$172.084
Operating Income$-376.746$-333.814$-237.631$-372.733$-376.721$-158.459
Total Non-Operating Income/Expense$-21.88$-33.587$-112.344$-8.438$-5.216$0.736
Pre-Tax Income$-398.626$-367.401$-349.975$-381.171$-381.937$-157.723
Income Taxes$1.798$0.608$-3.578$-32.034$-29.076$2.308
Income After Taxes$-400.424$-368.009$-346.397$-349.137$-352.861$-160.031
Other Income------
Income From Continuous Operations$-400.424$-368.009$-346.397$-349.137$-352.861$-160.031
Income From Discontinued Operations------
Net Income$-400.424$-368.009$-346.397$-349.137$-352.861$-160.031
EBITDA$-367.641$-325.69$-233.494$-265.622$-283.798$-154.238
EBIT$-376.746$-333.814$-237.631$-372.733$-376.721$-158.459
Basic Shares Outstanding545247383634
Shares Outstanding545247383634
Basic EPS$-7.43$-7.07$-7.36$-9.07$-9.79$-4.72
EPS - Earnings Per Share$-7.43$-7.07$-7.36$-9.07$-9.79$-4.72
# 2020 2019 2018 2017 2016 2015
Current Ratio2.75374.55117.69094.25957.141210.2816
Long-term Debt / Capital1.34470.79710.43441.01310.48210.4566
Debt/Equity Ratio-3.90083.9290.7682-77.35990.93090.8403
Gross Margin75.745176.858778.856510.2564-100
Operating Margin-263.4477-349.9539-428.0791-477862.8--1163.002
EBIT Margin-263.4477-349.9539-428.0791-477862.8--1163.002
EBITDA Margin-257.0808-341.4371-420.6266-340541--1132.022
Pre-Tax Profit Margin-278.7477-385.1648-630.4606-488680.8--1157.6
Net Profit Margin-280.005-385.8022-624.015-447611.5--1174.539
Asset Turnover0.21360.11050.07550.0002-0.0175
Inventory Turnover Ratio1.3080.81540.4267---
Receiveable Turnover6.95497.40078.98090.6446--
Days Sales In Receivables52.481249.319540.6418566.218--
ROE - Return On Equity229.7896-251.254-94.22289607.304-117.3661-48.2559
Return On Tangible Equity133.3631-1169.582-122.4632426.4373-252.3627-303.8083
ROA - Return On Assets-59.8001-42.6153-47.1141-95.7702-49.4629-20.5858
ROI - Return On Investment-79.2158-50.9751-53.2884-125.8188-60.782-26.2213
Book Value Per Share-3.17082.77417.2706-0.09387.83789.7604
Operating Cash Flow Per Share1.0225-1.48391.38510.0938-3.5705-0.9529
Free Cash Flow Per Share1.144-1.59761.33950.1599-3.5874-1.0161